Reading the tape
NASDAQ: AADI
Aadi Bioscience, Inc.
Healthcare · Biotechnology
Market Cap
$94.89M
52w High
$3.81
52w Low
$1.21
P/E
-2.37
Volume
62.61K
Outstanding Shares
46.29M
Not enough data to analyse price vs. fundamentals for this ticker.
Company profile
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.
CEODavid J. Lennon
SectorHealthcare
IndustryBiotechnology
Employees53
IPO dateFeb 16, 2018
Valuation
Forward P/E—
EV/EBITDA-8.92
Enterprise value$1.02B
Stock splits
Aug 27, 2021↓ Reverse
Every 15 shares became 1
Aug 18, 2021↑ Forward
Every 1 shares became 2
Profitability & growth
Revenue growth-100%
Gross margin0%▼100.00%vs FY2024
Operating margin0%▼516.71%vs FY2024
ROE-15.11%▲87.55%vs FY2024
Analyst consensus
RatingBuy
Target price$1.63▼20.49%
3
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Mar 12, 2026
Q2 FY26 · EPS est — · Revenue est —
View